Benzinga | Jan 18, 2022 10:39AM EST

Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Lowers Price Target to $585

Morgan Stanley maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and lowers the price target from $617 to $585.